Biofrontera Pharmaceuticals has taken over the entire operations of fellow German company bioLeads, which specialises in sourcing natural compounds from microorganisms.
bioLeads operates a lead discovery and optimisation platform comprising 45,000 microorganisms, a library of more than 2 million compounds in prepurified fractions and a synthetic chemistry unit. This capability will be combined with Biofrontera's biology and pharmacology resources to identify and develop new drug candidates, mostly for the treatment of central nervous system diseases.
Prior to the acquisition, Biofrontera and bioLeads collaborated successfully on the discovery of lead molecules for inflammatory pain, and the companies already have several ongoing drug discovery collaborations with leading international pharmaceutical companies, including Bayer, Janssen Pharmaceutica and Schering.
Commenting on the acquisition, Prof Hermann Lübbert, Biofrontera's chief executive, said: "The integration of bioLeads' abilities in chemistry will enable us to perform the pharmaceutical discovery process throughout all stages, and bring drugs into early development, both for in-house programs and our pharmaceutical partners."
Under the terms of the deal, all of bioLeads' activities and assets and the majority of its employees have been incorporated into Biofrontera Discovery, a wholly owned subsidiary of Biofrontera.